Molecular mechanism of a novel CD59-binding peptide sp22 induced tumor cells apoptosis

Journal of Cellular Biochemistry

Volumn 113, Issue 12, 2012, Pages 3810-3822

  Li, Bing ^a   Gao, Mei Hua ^a   Chu, Xian Ming ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

APOPTOSIS; CD59; PHAGE DISPLAY LIBRARY; SHORT PEPTIDE; sp22; TUMOR CELLS

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; CASPASE 3; CD59 ANTIGEN; FAS ANTIGEN; PROTEIN BCL 2; SP22 PEPTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; DRUG BINDING; DRUG SCREENING; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR ESCAPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD59; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BACTERIOPHAGE M13; BASE SEQUENCE; CASPASE 3; CATALYTIC DOMAIN; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CHO CELLS; COMPLEMENT ACTIVATION; CRICETINAE; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; IN SITU NICK-END LABELING; MCF-7 CELLS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PLASMIDS; PROTEIN BINDING; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867500994     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24258     Document Type: Article

References (60)

1. Askoxylakis V, Zitzmann S, Mier W, Graham K, Kramer S, von Wegner F, Fink RH, Schwab M, Eisenhut M, Haberkorn U,. 2005. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 11 (18): 6705-6712.
2. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL, Jackson DG,. 2002. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62 (5): 1315-1320.
3. Bockmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA, Putzer BM,. 2005. Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther 16 (11): 1267-1275.
4. Brummelkamp TR, Bernards R, Agami R,. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (5567): 550-553.
5. Chen B, Cao S, Zhang Y, Wang X, Liu J, Hui X, Wan Y, Du W, Wang L, Wu K, et al. 2009. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol 10: 63.
6. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, et al. 1997. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276 (5319): 1696-1699.
7. Fei P, Junyu N, Jiangfeng Y, Jingpin Y, Yuping W, Zhihui H, Jieliang W, Xianglin C, Shaomin Y, Jie Z,. 2004. Monoclonal antibodies against human tumor metastasis suppressor gene-1 (TMSG-1): preparation, characterization, and application. Hybrid Hybridomics 23 (5): 318-325.
8. Ferrieu-Weisbuch C, Michel S, Collomb-Clerc E, Pothion C, Deleage G, Jolivet-Reynaud C,. 2006. Characterization of prostate-specific antigen binding peptides selected by phage display technology. J Mol Recognit 19 (1): 10-20.
9. Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W,. 2001. Biopanning and rapid analysis of selective interactive ligands. Nat Med 7 (11): 1249-1253.
10. Green DR, Bissonnette RP, Cotter TG,. 1994. Apoptosis and cancer. Important Adv Oncol 11: 37-52.
11. Grobholz R, Zentgraf H, Kohrmann KU, Bleyl U,. 2002. Bax, Bcl-2, fas and Fas-L antigen expression in human seminoma: correlation with the apoptotic index. APMIS 110 (10): 724-732.
12. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, Lin M, Meisheng L, Junshan Y, Chengchao S,. 2002. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 277 (45): 43137-43142.
13. Hideshima T, Okada N, Okada H,. 1990. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 69 (3): 396-401.
14. Howell RC, Revskaya E, Pazo V, Nosanchuk JD, Casadevall A, Dadachova E,. 2007. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug Chem 18 (6): 1739-1748.
15. Hu S, Guo X, Xie H, Du Y, Pan Y, Shi Y, Wang J, Hong L, Han S, Zhang D, et al. 2006. Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential. Biochem Biophys Res Commun 341 (4): 964-972.
16. Ladner RC, Sato AK, Gorzelany J, de Souza M,. 2004. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9 (12): 525-529.
17. Lammers T, Hennink WE, Storm G,. 2008. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99 (3): 392-397.
18. Landon LA, Zou J, Deutscher SL,. 2004. Is phage display technology on target for developing peptide-based cancer drugs ? Curr Drug Discov Technol 1 (2): 113-132.
19. Lee G, Ge B,. 2009. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomark 5 (4): 177-188.
20. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC,. 2007. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67 (22): 10958-10965.
21. Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D,. 2011. Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomed 6: 59-69.
22. Lu Z, Murray KS, Van Cleave V, LaVallie ER, Stahl ML, McCoy JM,. 1995. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology (N Y) 13 (4): 366-372.
23. McConnell SJ, Dinh T, Le MH, Brown SJ, Becherer K, Blumeyer K, Kautzer C, Axelrod F, Spinella DG,. 1998. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries. Biol Chem 379 (10): 1279-1286.
24. McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG,. 1991. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res 544 (2): 315-319.
25. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS,. 2006. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103 (4): 1041-1046.
26. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ,. 1990. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1): 1-9.
27. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U,. 2005. Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem 16 (1): 237-240.
28. Molek P, Strukelj B, Bratkovic T,. 2011. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 16 (1): 857-887.
29. Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer PH,. 1993. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 81 (8): 2067-2075.
30. Ninomiya H, Stewart BH, Rollins SA, Zhao J, Bothwell AL, Sims PJ,. 1992. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. J Biol Chem 267 (12): 8404-8410.
31. Niu XJ, Wang ZR, Wu SL, Geng ZM, Zhang YF, Qing XL,. 2004. Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue. World J Gastroenterol 10 (5): 725-728.
32. Pasqualini R, Ruoslahti E,. 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380 (6572): 364-366.
33. Pasqualini R, Koivunen E, Ruoslahti E,. 1997. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15 (6): 542-546.
34. Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, et al. 2011. Liposomal tumor targeting in drug delivery utilizing MMP-2- and MMP-9-binding ligands. J Drug Deliv 2011: 160515.
35. Rollins SA, Sims PJ,. 1990. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144 (9): 3478-3483.
36. Samoylova TI, Morrison NE, Globa LP, Cox NR,. 2006. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer Agents Med Chem 6 (1): 9-17.
37. Schooltink H, Rose-John S,. 2005. Designing cytokine variants by phage-display. Comb Chem High Throughput Screen 8 (2): 173-179.
38. Scott JK, Smith GP,. 1990. Searching for peptide ligands with an epitope library. Science 249 (4967): 386-390.
39. Seifert PS, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S,. 1992. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 96 (2-3): 135-145.
40. Seya T, Tejima H, Fukuda H, Hara T, Matsumoto M, Hatanaka M, Sugita Y, Masaoka T,. 1993. Acute promyelocytic leukemia with CD59 deficiency. Leuk Res 17 (10): 895-896.
41. Sharon J, Liebman MA, Williams BR,. 2005. Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem 96 (2): 305-313.
42. Smith GP,. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (4705): 1315-1317.
43. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, Chou CH, Hu CL, Kuo ML, Hsieh CY, et al. 2005. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 65 (11): 4827-4835.
44. Sugita Y, Mazda T, Tomita M,. 1989. Amino-terminal amino acid sequence and chemical and functional properties of a membrane attack complex-inhibitory factor from human erythrocyte membranes. J Biochem 106 (4): 589-592.
45. Sugita Y, Nakano Y, Oda E, Noda K, Tobe T, Miura NH, Tomita M,. 1993. Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem 114 (4): 473-477.
46. Tipps ME, Lawshe JE, Ellington AD, Mihic SJ,. 2010. Identification of novel specific allosteric modulators of the glycine receptor using phage display. J Biol Chem 285 (30): 22840-22845.
47. Treon SP, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC,. 2000. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 11 (Suppl 1): 107-111.
48. Uesu T, Mizuno M, Inoue H, Tomoda J, Tsuji T,. 1995. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest 72 (5): 587-591.
49. Vakeva A, Laurila P, Meri S,. 1993. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol 143 (1): 65-75.
50. Venneker GT, Das PK, Meinardi MM, van Marle J, van Veen HA, Bos JD, Asghar SS,. 1994. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins are constitutively down-regulated in psoriatic skin. J Pathol 172 (2): 189-197.
51. Vrielink J, Heins MS, Setroikromo R, Szegezdi E, Mullally MM, Samali A, Quax WJ,. 2010. Synthetic constrained peptide selectively binds and antagonizes death receptor 5. FEBS J 277 (7): 1653-1665.
52. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S,. 2002. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 100 (12): 3897-3902.
53. Weiss L, Okada N, Haeffner-Cavaillon N, Hattori T, Faucher C, Kazatchkine MD, Okada H,. 1992. Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. AIDS 6 (4): 379-385.
54. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ,. 1996. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273 (5274): 458-464.
55. Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, Zeng Y, Wang Y, Nie C, Yang Y, et al. 2010. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med 14 (1-2): 351-356.
56. Yang W, Luo D, Wang S, Wang R, Chen R, Liu Y, Zhu T, Ma X, Liu R, Xu G, et al. 2008. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 14 (17): 5494-5502.
57. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA, et al. 1996. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 93 (14): 7381-7386.
58. Zaltzman AB, Van den Berg CW, Muzykantov VR, Morgan BP,. 1995. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. Biochem J 307 (Pt 3): 651-656.
59. Zitzmann S, Kramer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U,. 2005. Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. J Nucl Med 46 (5): 782-785.
60. Zitzmann S, Kramer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U,. 2007. Identification and evaluation of a new tumor cell-binding peptide FROP-1. J Nucl Med 48 (6): 965-972.